Related Experiment Videos
Detection of interferon inhibitors or antagonists in gastrointestinal malignancies
K D Karmaniolas1, T S Papalampros, E D Papavassiliou
13rd Department of Internal Medicine, NIMTS Hospital, Athens, Greece.
Background/Aims:
The aim of this study was to investigate the IFN-inhibiting activity in sera from patients with gastrointestinal malignancies, exerted in a variety of cellular types, as well as to elucidate the determinants of cellular sensitivity to such IFN-inhibitors.
Methodology:
Sera from 16 patients with gastric cancer and 18 with colon cancer were tested, while sera from 37 healthy blood donors were used as controls. All serum samples, collected before any kind of treatment, were tested for IFN-blocking and endogenous IFN-like activity. These activities were determined by assaying the inhibition of the vesicular stomatitis virus specific cytopathic effect in three cell lines: A549 cells, intestine 407 and Chang liver cells.
Results:
There was no endogenous IFN in any of the serum samples of patients or controls. Concerning the IFN blocking activity of serum, there was no significant difference between gastric and colon cancer, while a marked variability was prominent depending on the cell line used. 76.4% of serum samples exerted IFN-blocking activity in the A549 cells, 47.05% in the Int-407 cell line and 32.3% in the Chang Liver cells. No control sample had IFN-blocking activity in any of the cell lines tested.
Conclusions:
The results support a cytokine and cytokine inhibitors network, mediating pathophysiological events at the cellular level as well as the whole organism. The limited responsiveness of many neoplasias, including digestive system cancer, to IFN treatment might be due to the presence of IFN inhibitors in the patient's serum.
Insights
Serum from gastrointestinal cancer patients contains interferon (IFN)-inhibiting activity, which varies by cell type. This IFN-blocking activity may explain why some cancers, like digestive system cancers, respond poorly to IFN treatment.
Area of Science:
- Immunology
- Oncology
- Cell Biology
Background:
- Interferons (IFNs) are crucial for immune response and cancer therapy.
- Gastrointestinal malignancies can exhibit complex interactions with immune signaling pathways.
- Understanding IFN-inhibiting factors in cancer is vital for therapeutic development.
Purpose of the Study:
- To investigate interferon (IFN)-inhibiting activity in sera from gastrointestinal cancer patients.
- To assess the cellular specificity of these IFN-inhibiting activities.
- To identify factors influencing cellular sensitivity to IFN inhibitors.
Main Methods:
- Sera from gastric cancer (n=16), colon cancer (n=18), and healthy donors (n=37) were analyzed.
- Interferon (IFN)-blocking and endogenous IFN-like activities were measured.
- Cytopathic effect inhibition of vesicular stomatitis virus was assessed in A549, Int-407, and Chang liver cells.
Main Results:
- No endogenous IFN activity was detected in patient or control sera.
- IFN-blocking activity in sera varied significantly across cell lines: 76.4% in A549, 47.05% in Int-407, and 32.3% in Chang Liver cells.
- No IFN-blocking activity was observed in control sera, indicating cancer-specific inhibition.
Conclusions:
- Patient sera contain IFN-inhibiting factors that act differentially on various cell types.
- The presence of these IFN inhibitors may contribute to the limited responsiveness of digestive system cancers to IFN therapy.
- A complex network of cytokines and inhibitors influences pathophysiological events in cancer.